Goodwill and Other Intangible Assets (Notes)
 3 Months Ended
Mar. 31, 2015
Finite-Lived Intangible Assets, Net [Abstract]  
Goodwill and Intangible Assets Disclosure [Text Block]
Note 7: Goodwill and Other Intangibles
Goodwill and other indefinite-lived intangible assets were as follows:
 
March 31, 2015
 
December 31, 2014
Goodwill (by segment):
 
 
 
Human pharmaceutical products
$
1,359.1

 
$
1,359.4

Animal health
2,587.8

 
398.7

Total goodwill
3,946.9

 
1,758.1

In-process research and development
295.7

 
11.4

Total indefinite-lived intangible assets
$
4,242.6

 
$
1,769.5


The increases in goodwill for the animal health segment and acquired IPR&D in 2015 are due to the acquisition of Novartis AH (Note 3).
The components of finite-lived intangible assets were as follows:
 
March 31, 2015
 
December 31, 2014
Description
Carrying
Amount—
Gross
 
Accumulated
Amortization
 
Carrying
Amount—
Net
 
Carrying
Amount—
Gross
 
Accumulated
Amortization
 
Carrying
Amount—
Net
Marketed products
$
7,614.3

 
$
(3,062.0
)
 
$
4,552.3

 
$
5,684.3

 
$
(2,915.6
)
 
$
2,768.7

Other
147.4

 
(47.7
)
 
99.7

 
149.3

 
(45.2
)
 
104.1

Total finite-lived intangible assets
$
7,761.7

 
$
(3,109.7
)
 
$
4,652.0

 
$
5,833.6

 
$
(2,960.8
)
 
$
2,872.8


The increase in marketed products in 2015 is due to the acquisition of Novartis AH (Note 3).
Amortization expense related to these finite-lived intangibles was $154.2 million and $131.9 million for the three months ended March 31, 2015 and 2014, respectively.
See Note 3 for further discussion of intangible assets acquired in recent business combinations.